RxDoctor Payments Data

Marcia Cleavenger, APRN

Psychiatric/Mental Health · Salina, KSNPI 1073715322

Payments from drug & device makers

$2,633in general payments, 2019–2025

Across 160 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$581
  • Otsuka America Pharmaceutical, Inc.$301
  • Lundbeck LLC$246
  • Neurocrine Biosciences, Inc.$204
  • Takeda Pharmaceuticals U.S.A., Inc.$162
  • Acadia Pharmaceuticals Inc$159
  • plus $981 from 17 others

What the payments were for

  • Food & beverage$2,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,633 in reported general payments places this provider in the 75th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$42,798
Medicare patients
175
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$158,008
TrintellixVortioxetine Hydrobromide61$42,746
VraylarCariprazine Hcl15$20,334
BelsomraSuvorexant17$7,458
FetzimaLevomilnacipran Hcl14$6,899
Aripiprazole170$5,092
Desvenlafaxine Succinate ErDesvenlafaxine Succinate105$4,045
Duloxetine Hcl234$3,762
Lisdexamfetamine Dimesylate13$3,511
Lurasidone Hcl27$3,136
Bupropion XlBupropion Hcl168$2,762
Quetiapine Fumarate191$2,679
Vilazodone Hcl33$2,089
Quetiapine Fumarate ErQuetiapine Fumarate36$1,882
Venlafaxine Hcl ErVenlafaxine Hcl115$1,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$204$158,00819 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$162$42,74661 claims
AbbVieVraylar, Fetzima$581$27,23329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Salina

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →